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The clinical phenotype of sickle cell/beta+-thalassemia (Hb
S/+-Thal) is highly variable, and severity is associated with
the quantitative degree of decrease in the production of the
beta globin chains.1 Evidence shows that differences in the
production of hemoglobin A (Hb A) and severity correspond
to different molecular beta-thalassemia (-Thal) mutations.2
A previous report proposed a classiﬁcation of Hb S/+-Thal
phenotypes based on the relative concentration of Hb A: Type
I: 1–7% of Hb A; Type II: 7–14% of Hb A; and Type III: 14–25% of Hb
A.2 However, some -Thal mutations lead to low impairment
of -globin production and the resulting phenotype does not
ﬁt this proposed classiﬁcation. In a single patient case report,
the −92 (C>T) mutation was associated with a high level of
Hb A (45%) in an adult Sicilian patient with Hb S/+-Thal.3
Recently, a combination of two sequence variants, IVS-II-
839 (T>C) and IVS-II-844 (C>A), was associated with a very
mild phenotype of sickle cell disease (SCD).4 Because of the
marked clinical variability of Hb S/+-Thal patients, molecular
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reserved.predictors of disease severity would be helpful to guide treat-
ment choices in children with this genotype. The objective
of this study was to characterize the hematological parame-
ters, clinical features, and molecular basis of very mild forms
of Hb S/+-Thal in a newborn cohort of Minas Gerais state,
Brazil.
Case  series
This is a case series involving children from the Minas Gerais
State SCD newborn cohort, Brazil. As part of a yet incomplete
study, 56 out of 96 (58.3%) children with Hb S/0-thal or Hb
S/+-Thal from that cohort born between 1998 and 2013 had
already been submitted to DNA analysis to identify the -thal
mutations causing Hb S/-thal. Children were considered to be
eligible for this report if they had Hb A concentrations equal to
or above 25% conﬁrmed by hemoglobin electrophoresis. Chil--000, Brazil.
dren had hemoglobin FSA patterns diagnosed by isoelectric
focusing and high-performance liquid chromatography in the
Newborn Screening Program and have been followed up since
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iagnosis in the outpatient care unit of Fundac¸ão Hemominas,
hich is situated in the state capital, Belo Horizonte.
Laboratory and clinical data were retrieved by chart review
fter approval of the local institutional review board. Hema-
ologic and genetic studies were performed on the parents of
wo children to elucidate the inheritance pattern of the -thal
utations.
Complete blood count was performed using an electronic
ell counter (model T-890, Beckman Coulter, Hialeah, FL, USA
r Cell-Dyn ruby, Abbott, IL, USA). Hemoglobin electrophore-
is was conducted in an alkaline medium (SPIFE kits, Helena
aboratories, Beaumont, TX, USA) and the percentage of Hb
 was quantiﬁed by radial immunodiffusion (HbF QUIPlate,
elena Laboratories, Beaumont, TX, USA). The reticulocyte
ount was measured by optical microscopy using brilliant cre-
yl blue.
Genomic DNA was isolated with a QIAGEN kit (QIAamp®
NA Blood Mini Kit, Qiagen, Hilden, Germany). The HBB gene
as ampliﬁed with speciﬁc primers. Sequence data were
enerated with an ABI 3130xl capillary sequencer (Applied
iosystems, Foster City, CA, USA) using standard protocols. A
ultiplex gap polymerase chain reaction (PCR) assay was used
o detect the most common alpha-thalassemia deletions.5
Written informed consent was obtained from parents or
uardians of every child in accordance with the norms of the
eclaration of Helsinki guidelines with the child’s assent being
btained when appropriate.
The study included four unrelated children with diagno-
is of Hb S/+-Thal. The mean age was 8.0 ± 2.4 years (range:
.5–11.2 years) and all were male. These children were fol-
owed for a mean of 7.7 ± 2.4 years (range: 5.2–11 years).
Two children had a −92 (C>T) mutation (HBB:c.−142C>T)
nd two had IVS-II-844 (C>A) (HBB:c.316-7C>A) plus IVS-II-839
T>C) (HBB:c.316-12T>C) mutations (Figure 1). Genetic family
tudies showed that the IVS-II-844 (C>A) and IVS-II-839 (T>C)
utations were in cis in both children because both muta-ions were inherited from just one of the parents. No child
ad co-inherited alpha-thalassemia deletions. The mean rel-
tive concentration of Hb A was 40.4% and that of Hb S was
200
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igure 1 – Sequencing four-color chromatogram showing
A) IVS-II-844 (C>A) and IVS-II-839 (T>C) mutations in cis;
nd (B) the −92 (C>T) mutation. 1 5;3  7(3):198–201 199
54%. Genetic, laboratory, and family data are summarized in
Table 1.
All children were clinically oligosymptomatic and led nor-
mal  lives. Except for an obstruction of the airways caused
by adenoid glands, child number I was asymptomatic dur-
ing the follow-up period. Child number II suffered from
two infectious episodes: virus infection, for which a ﬁve-
day hospitalization was required, and impetigo, treated with
benzathine penicillin. He has had recurrent headaches, but
the neurologic physical examination was normal. Except
for an episode of sinusitis, child number III was asymp-
tomatic during the follow-up period. Child number IV
suffered from recurrent headaches, but the neurologic phys-
ical examination was normal. None of the children have had
severe acute clinical manifestations of SCD such as acute
painful crises, stroke, acute chest syndrome, or acute splenic
sequestration.
Discussion
Our study described a group of Hb S/+-Thal patients with nor-
mal  or nearly normal hematological data and the absence of
complications attributable to SCD. To the best of our knowl-
edge, this is the ﬁrst study to report on the occurrence of −92
(C>T), and IVS-II-844 (C>A)/IVS-II-839 (T>C) -thal mutations
in Brazil.
The degree of -chain synthesis in Hb S/+-Thal patients
depends primarily on the -Thal molecular mutation. The
IVS-II-844 (C>A)/IVS-II-839 (T>C) mutation affects the consen-
sus splice site and interferes with processing of the primary
mRNA transcript. It modiﬁes the conserved polypyrimidine
tract of the splice acceptor site causing a reduction of beta
globin chain expression to around 60% of normal.4,6 Carriers
of the mutations described in this report showed a mean Hb
A level of 39.7% and were oligosymptomatic. This ﬁnding is
consistent with the ﬁrst report of these two  variants in four
unrelated Canadian families of African ancestry. The probands
were asymptomatic Hb S/+-Thal patients and the adults had
Hb A levels of about 44%.4 This is the second study worldwide
to report these two linked sequence variants in cis.  The IVS-
II-844 mutation has also been identiﬁed in beta-thalassemia
patients without the concomitant IVS-II-839 mutation being
reported.7–9
The −92 (C>T) is a transcriptional mutation affecting the
-globin gene promoter.6 This study showed that this muta-
tion leads to a nearly asymptomatic phenotype of SCD with a
mean Hb A level of 41.4%. This ﬁnding is in agreement with
those of other investigators.3 This mutation was ﬁrst reported
in association with the S allele in a Sicilian adult with a high
level of Hb A (45%) who was clinically asymptomatic.3 This
is the second study to report the −92 (C>T) mutation in Hb
S/+-Thal patients. Heterozygous beta-thalassemia patients
affected by this mutation also showed a silent form of disease,
whereas compound heterozygotes with codon 39 or IVS-II-745
mutations developed beta-thalassemia intermedia.10According to our ﬁndings and those of other
investigators,3,4 both the −92 (C>T) mutation and the
IVS-II-844 (C>A)/IVS-II-839 (T>C) combination cause a very
mild form of Hb S/+-Thal. These mutations do not ﬁt into
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Table 1 – Genetic, laboratory, and family characteristics of children with very mild forms of S+-thal in Minas Gerais, Brazil.
Family I Family  II Family  III Family IV
Family relationship Child I Mother Father Child II Mother Father Child III Child IV
Beta-globin
genotype
S/Thal  IVSII−844/839 A/Thal  IVSII−844/839 NA S/Thal  IVSII−844/839 S/A A/Thal  IVSII−844/839 S/Thal  −92  C>T S/Thal  −92  C>T
Age (years) 7.4 8.0 5.5 11.2
Gender Male Female Male Male Female Male Male Male
Hemoglobin (g/dL) 12.9 ± 0.4 11.2 16.1 12.0 ± 0.8 14.5 16.8 11.4 ± 1.1 11.5 ± 0.6
Hematocrit (%) 40 ± 1.1 35.1 47.1 37.5 ± 2.5 43 50.2 35.4 ± 2.1 35.3 ± 1.4
Red blood cells
(106/L)
5.5  ± 0.3 4.1 5.5 5.3 ± 0.3 4.5 5.8 4.7 ± 1.1 4.6 ± 0.2
Mean corpuscular
volume (fL)
74.5 ± 3.4 85.7 85.3 75.0 ± 1.1 95.5 86.2 78 ± 0.8 78.4 ± 2.5
Mean corpuscular
hemoglobin (pg)
24 ± 0.7 27.2 29.1 23.5 ± 0.4 33.7 33.5 25.7 25.2 ± 1.2
Reticulocyte count
(%)
1.2  ± 0.7 2.1 0.7 1.1 ± 0.4 1 0.9 0.9 ± 0.7 0.9 ± 0.6
Leukocytes (103/L) 11.3 ± 2.6 8.2 7.8 5.5 ± 0.7 8.5 3.5 9.6 ± 2.5 5.8 ± 1.0
Platelets (103/L) 387.7 ± 50 239.5 233 273.8 ± 26.5 180 169 255.5 ± 14.8 312.1 ± 63.6
Hemoglobin A (%) 38.3 ± 1.3 97 51 41.0 ± 2.2 52 95.5 41 41.4 ± 0.9
Hemoglobin S (%) 55.2 ± 2.1 0 45 54.2 ± 1.8 44 0 54 53.6 ± 0.5
Hemoglobin F (%) 3.5 ± 1.0 1 2 2.0 ± 0.7 2 1.5 2 1.8 ± 0.4
Hemoglobin A2 (%) 3.0 ± 0 2 2 2.8 ± 0.4 2 3 3 3.2 ± 0.8
Alpha-globin
genotype
/ / NA / / / / /
Means and standard deviations refer to several values for each patient during their clinical follow-up at Hemominas Blood Center. NA: DNA not available.
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he Hb S/+-Thal phenotypic classiﬁcation as proposed by
erjeant et al. based on the amount of Hb A produced.2 This
henotypic classiﬁcation was based on data from Jamaican
atients with SCD and so it does not represent all Hb S/+-Thal
atients worldwide. As the original classiﬁcation is limited
o patients with 1–25% of Hb A, we  accordingly propose here
 fourth Hb S/+-Thal phenotype, with an amount of Hb A
anging from 25 to 45%. Molecular diagnosis of these types of
b S/+-Thal by newborn screening programs confer a ‘good’
rognosis and will surely reduce anxiety and stress in family
aregivers of children recently diagnosed with this subtype of
CD.
A few limitations of our study warrant mention. Given that
he studied cases were children, possible long-term compli-
ations cannot be predicted. Owing to the small number of
atients, the present report may not fully represent these rare
b S/+-Thal genotypes.
In summary, −92 (C>T) and IVS-II-844 (C>A)/IVS-II-839
T>C) mutations associated with the S allele lead to a very
ild form of Hb S/+-Thal, which we have named Type IV
25–45% of Hb A). Research is needed to determine whether
ther modifying genetic or environmental factors may aggra-
ate the phenotype of affected patients.
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